光动力疗法治疗胶质母细胞瘤的叙述性综述
本叙述性综述全面回顾了光动力疗法(PDT)治疗胶质母细胞瘤(GBM)的机制、光敏剂、递送系统及临床证据。PDT通过活性氧生成、血管破坏和免疫激活发挥肿瘤特异性细胞毒作用,早期临床试验(如INDYGO和talaporfin sodium研究)报告了良好的安全性及生存延长。PDT有望成为GBM治疗的辅助手段,但需随机对照试验进一步验证。
要点
- PDT通过活性氧、血管破坏和免疫激活发挥肿瘤特异性杀伤作用。
- 5-ALA、氯素和酞菁类光敏剂在胶质瘤细胞中选择性积聚,提高治疗精准度。
- 早期临床试验显示PDT安全性良好并延长新诊断及复发GBM患者生存。
核心结论
- PDT为改善GBM局部控制提供了新的靶向方法,有望成为可行的辅助治疗手段。
- 需通过随机对照试验进一步验证疗效并获得监管批准,最终整合入标准神经肿瘤实践。
研究设计与样本
- 叙述性综述,全面回顾PDT治疗GBM的临床前与临床文献。
- 重点评估PDT作用机制、免疫调节效应、递送系统及与其他方案的联合潜力。
- 综述并描述了该主题的所有临床试验。
主要发现
- PDT通过活性氧生成、血管破坏和免疫激活发挥肿瘤特异性细胞毒效应。
- 5-ALA、氯素和酞菁类光敏剂在胶质瘤细胞中选择性积聚,增强治疗精准度。
- 临床前研究表明PDT可诱导凋亡、提高血脑屏障通透性并与现有化疗药物协同。
- 早期临床试验(包括INDYGO和talaporfin sodium研究)报告了良好的安全性及在新诊断和复发GBM患者中的生存延长。
临床怎么用
- PDT可作为GBM局部控制的辅助治疗选择,尤其适用于新诊断或复发患者。
- 光敏剂选择(如5-ALA、氯素、酞菁类)影响治疗精准度,需结合递送系统优化。
- 联合现有化疗药物可能增强疗效,但需进一步临床验证。
局限性
- 现有证据主要来自临床前研究和早期临床试验,缺乏随机对照试验验证。
- PDT的疗效和监管批准尚待进一步临床确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glioblastoma (GBM) remains one of the most aggressive primary brain tumors with poor survival outcomes and a lack of approved therapies. A promising novel approach for GBM is the application of photodynamic therapy (PDT), a localized, light-activated treatment using tumor-selective photosensitizers. This narrative review describes the mechanisms, delivery systems, photosensitizers, and available evidence regarding the potential of PDT as a novel therapeutic approach for GBM. METHODS: A comprehensive review of the preclinical and clinical literature was conducted on the role of PDT for GBM. Special emphasis was placed on PDT's mechanisms of action, immunomodulatory effects, delivery systems, and combinatorial potential with other treatment regimens. All clinical trials on this topic were reviewed and described. RESULTS: PDT exerts tumor-specific cytotoxic effects via reactive oxygen species generation, vascular disruption, and immune activation. Photosensitizers such as 5-aminolevulinic acid (5-ALA), chlorins, and phthalocyanines demonstrate selective accumulation in glioma cells and enhance treatment precision. Preclinical studies demonstrate that PDT can induce apoptosis, improve blood-brain barrier permeability, and synergize with existing chemotherapeutics. Early-phase clinical trials, including the INDYGO and talaporfin sodium-based studies, report promising safety profiles and extended survival in newly diagnosed and recurrent GBM patients. CONCLUSION: PDT offers a novel targeted approach for improving local control of GBM. With continued innovation in photosensitizer design, delivery technologies, and combinatorial strategies, PDT holds promise as a viable therapeutic adjunct in GBM treatment. Further clinical validation through randomized controlled trials is warranted to establish its efficacy and gain regulatory approval with the eventual goal of integration into standard neuro-oncology practice.
引用
- Price G, Frederico SC, Colan J, et al. Photodynamic therapy for glioblastoma: a narrative review. J Neurooncol. 2025. PMID: 40924328. doi:10.1007/s11060-025-05217-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。